Compare RYTM & TFPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | TFPM |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.8B |
| IPO Year | 2017 | N/A |
| Metric | RYTM | TFPM |
|---|---|---|
| Price | $112.03 | $33.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $125.77 | $32.33 |
| AVG Volume (30 Days) | ★ 887.7K | 499.2K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 0.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.01 |
| Revenue | $174,334,000.00 | ★ $344,001,000.00 |
| Revenue This Year | $47.34 | $42.63 |
| Revenue Next Year | $57.18 | $11.85 |
| P/E Ratio | ★ N/A | $34.32 |
| Revenue Growth | ★ 54.92 | 39.55 |
| 52 Week Low | $45.91 | $14.51 |
| 52 Week High | $122.20 | $35.77 |
| Indicator | RYTM | TFPM |
|---|---|---|
| Relative Strength Index (RSI) | 57.51 | 62.15 |
| Support Level | $109.59 | $32.35 |
| Resistance Level | $122.20 | $35.77 |
| Average True Range (ATR) | 5.23 | 1.14 |
| MACD | 1.04 | 0.13 |
| Stochastic Oscillator | 54.25 | 59.58 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Triple Flag Precious Metals Corp is a streaming and royalty company focused on precious metals. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Mexico, Mongolia, Peru, South Africa, and the United States. Its diversified portfolio of streams and royalties comprises long-life mining assets, including the Northparkes copper-gold mine in Australia, the Cerro Lindo polymetallic mine in Peru, the Fosterville gold mine in Australia, the Buritica gold mine in Colombia, and the Impala Bafokeng Operations in South Africa among others. A majority of its revenue is derived through its interests in various gold streams. Geographically, the company derives maximum revenue from Australia, followed by Peru and other regions.